OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclinD‐CDK4 /6 pathway alterations in the DutchDRUP and AustralianMoST trials
Laurien J. Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 7, pp. 1413-1422
Open Access | Times Cited: 14
Laurien J. Zeverijn, Eleonora J. Looze, Subotheni Thavaneswaran, et al.
International Journal of Cancer (2023) Vol. 153, Iss. 7, pp. 1413-1422
Open Access | Times Cited: 14
Showing 14 citing articles:
The pathway alteration load is a pan-cancer determinant of outcome of targeted therapies: results from the Drug Rediscovery Protocol (DRUP)
Karlijn Verkerk, Laurien J. Zeverijn, Joris van de Haar, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104112-104112
Open Access | Times Cited: 2
Karlijn Verkerk, Laurien J. Zeverijn, Joris van de Haar, et al.
ESMO Open (2025) Vol. 10, Iss. 1, pp. 104112-104112
Open Access | Times Cited: 2
Treatment of Thoracic SMARCA4-Deficient Undifferentiated Tumors: Where We Are and Where We Will Go
Vito Longo, Annamaria Catino, Michele Montrone, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3237-3237
Open Access | Times Cited: 10
Vito Longo, Annamaria Catino, Michele Montrone, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 6, pp. 3237-3237
Open Access | Times Cited: 10
Generating and using real-world data: A worthwhile uphill battle
Karin Verkerk, Emile E. Voest
Cell (2024) Vol. 187, Iss. 7, pp. 1636-1650
Open Access | Times Cited: 8
Karin Verkerk, Emile E. Voest
Cell (2024) Vol. 187, Iss. 7, pp. 1636-1650
Open Access | Times Cited: 8
The evolution of precision oncology: The ongoing impact of the Drug Rediscovery Protocol (DRUP)
Soemeya F. Haj Mohammad, Hans Timmer, Laurien J. Zeverijn, et al.
Acta Oncologica (2024) Vol. 63, pp. 368-372
Open Access | Times Cited: 6
Soemeya F. Haj Mohammad, Hans Timmer, Laurien J. Zeverijn, et al.
Acta Oncologica (2024) Vol. 63, pp. 368-372
Open Access | Times Cited: 6
PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe
Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, et al.
Acta Oncologica (2024) Vol. 63, pp. 385-391
Open Access | Times Cited: 5
Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, et al.
Acta Oncologica (2024) Vol. 63, pp. 385-391
Open Access | Times Cited: 5
Osimertinib and palbociclib in an EGFR-mutated NSCLC with primary CDK4 amplification after progression under osimertinib
Vincent D. de Jager, Jos A. Stigt, Maarten Niemantsverdriet, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Vincent D. de Jager, Jos A. Stigt, Maarten Niemantsverdriet, et al.
npj Precision Oncology (2024) Vol. 8, Iss. 1
Open Access | Times Cited: 3
Cancer therapy by cyclin-dependent kinase inhibitors (CDKIs): bench to bedside.
Ali Hassanzadeh, Navid Shomali, Amin Kamrani, et al.
PubMed (2024) Vol. 23, pp. 862-882
Closed Access | Times Cited: 2
Ali Hassanzadeh, Navid Shomali, Amin Kamrani, et al.
PubMed (2024) Vol. 23, pp. 862-882
Closed Access | Times Cited: 2
Palbociclib in Patients With Soft Tissue Sarcoma With CDK4 Amplifications: Results From the Targeted Agent and Profiling Utilization Registry Study
Scott M. Schuetze, Michael Rothe, Pam K. Mangat, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Scott M. Schuetze, Michael Rothe, Pam K. Mangat, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Palbociclib in Solid Tumor Patients With Genomic Alterations in the cyclinD-cdk4/6-INK4a-Rb Pathway: Results From National Cancer Institute-Children's Oncology Group Pediatric Molecular Analysis for Therapy Choice Trial Arm I (APEC1621I)
Margaret E. Macy, Rajen Mody, Joel M. Reid, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Margaret E. Macy, Rajen Mody, Joel M. Reid, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access | Times Cited: 2
Efficacy of Pembrolizumab and Biomarker Analysis in Patients with WGS-Based Intermediate to High Tumor Mutational Load: Results from the Drug Rediscovery Protocol
Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3735-3746
Closed Access | Times Cited: 1
Birgit S. Geurts, Laurien J. Zeverijn, Lindsay V.M. Leek, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 17, pp. 3735-3746
Closed Access | Times Cited: 1
Phase 2 Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Sub-protocol Z1C
Mark H. O’Hara, Opeyemi A. Jegede, Mark A. Dickson, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 56-64
Closed Access | Times Cited: 1
Mark H. O’Hara, Opeyemi A. Jegede, Mark A. Dickson, et al.
Clinical Cancer Research (2024) Vol. 31, Iss. 1, pp. 56-64
Closed Access | Times Cited: 1
Glutaminase as a metabolic target of choice to counter acquired resistance to Palbociclib by colorectal cancer cells
Míriam Tarrado‐Castellarnau, Carles Foguet, Josep Tarragó‐Celada, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Míriam Tarrado‐Castellarnau, Carles Foguet, Josep Tarragó‐Celada, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Palbociclib in Patients With Head and Neck Cancer and Other Tumors With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study
Francis P. Worden, Evan Pisick, Michael Rothe, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access
Francis P. Worden, Evan Pisick, Michael Rothe, et al.
JCO Precision Oncology (2024), Iss. 8
Closed Access
Effective treatment strategies and key factors influencing therapeutic efficacy in advanced SMARCA4-deficient non-small cell lung cancer
Hui Liu, Qiyuan Hong, Shuohan Zheng, et al.
Lung Cancer (2024) Vol. 198, pp. 108022-108022
Open Access
Hui Liu, Qiyuan Hong, Shuohan Zheng, et al.
Lung Cancer (2024) Vol. 198, pp. 108022-108022
Open Access
